



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/722,086	11/24/2003	Charles B. Chapman	100201800-1	7958
22879	7590	10/15/2007	EXAMINER	
HEWLETT PACKARD COMPANY			BOWERS, NATHAN ANDREW	
P O BOX 272400, 3404 E. HARMONY ROAD			ART UNIT	PAPER NUMBER
INTELLECTUAL PROPERTY ADMINISTRATION			1797	
FORT COLLINS, CO 80527-2400				

MAIL DATE	DELIVERY MODE
10/15/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/722,086	CHAPMAN, CHARLES B.	
	Examiner	Art Unit	
	Nathan A. Bowers	1797	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 14 August 2007.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-37 is/are pending in the application.
- 4a) Of the above claim(s) 15-35 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-14, 36 and 37 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____. | 6) <input type="checkbox"/> Other: _____. |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 14 August 2007 has been entered.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any

Art Unit: 1797

evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

1) Claims 1-14, 36 and 37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wilding (US 20030199081) in view of Mowry (US 7078237) and/or Doung (US 20020177135).

With respect to claims 1, 5-11, 12, 36 and 37, Wilding discloses a disposable biochip comprising a substrate and a region on the substrate having components configured to interact with a biological substance. More specifically, Wilding discloses a PCR chamber (Figure 1:22) within which nucleic acid samples interact with reagents required for amplification. This is described in paragraph [0040] and [0044]. Paragraphs [0014] and [0045] indicate that the temperature of the PCR chamber is regulated by microprocessor controlled resistance heaters positioned in the substrate. These resistance heaters are configured to assist the reagent components in interacting with the nucleic acid samples. According to the protocol of PCR, the heaters move the temperature of the biochip through at least one heating cycle to amplify the DNA. Paragraph [0052] additionally states that the microprocessor acts as a bio-analysis device capable of detecting and recording data obtained during an assay. Wilding, however, does not state that the heating devices are configured to generate heat sufficient to pyrolyze the nucleic acid sample following normal thermal cycling procedures.

Mowry discloses a biochip that comprises a substrate (Figure 1:120) and a heating device (Figure 1:110) integrated with the substrate in order to form a pyrolysis stage (Figure 2:100).

Art Unit: 1797

This is described in column 4, lines 8-30. Column 6, lines 30-47 indicate that the heating device is configured to generate heat sufficient to pyrolyze a biological substance disposed within the biochip.

Doung discloses a disposable biochip capable of performing PCR and facilitating the detection of nucleic acid analytes through the use of hybridization arrays. Doung indicates that a plurality of heating means and thermocontrollers are utilized to regulate the temperature within reaction chambers during amplification and detection processes. In paragraph [0326], Doung teaches that it is known in the art to use heating means disposed upon a biochip to create extreme temperatures over a sufficient period of time sufficient to kill and destroy a biological sample.

Wilding, Mowry and Doung are analogous art because they are from the same field of endeavor regarding biochips.

At the time of the invention, it would have been obvious to utilize the heating means disclosed by Wilding to generate extreme temperatures in order to pyrolyze biological substances following normal thermalcycling procedures. Mowry indicates in column 4, lines 8-30 that resistive heating elements, similar to those disclosed by Wilding, are capable of producing temperatures sufficient to pyrolyze a variety of biochemical compounds. Doung teaches in paragraph [0326] that it is beneficial to destroy biological samples via heat treatment after analysis because many samples are dangerous and would pose health problems to operators if contacted.

With respect to claims 2 and 13, Wilding and Mowry/Doung disclose the apparatus and method set forth in claims 1 and 9 as set forth in the 35 U.S.C. 103 rejection above. Although

Art Unit: 1797

not expressly disclosed, it can be inferred that the decontamination procedures taught by Mowry and Doung rid the biochip substantially free of contaminants.

With respect to claims 3 and 14, Wilding and Mowry/Doung disclose the apparatus and method set forth in claims 1 and 9 as set forth in the 35 U.S.C. 103 rejection above. Additionally, Wilding discloses in paragraph [0008] that the disclosed apparatus is intended to conduct clinical tests for paternity and genetic and infectious diseases. These tests (clearly paternity testing) use biological substances obtained from a human source. Doung also discloses the use of assays that utilize biological substances from a human source.

With respect to claim 4, Wilding and Mowry/Doung disclose the apparatus set forth in claim 1 as set forth in the 35 U.S.C. 103 rejection above. Wilding additionally indicates in paragraphs [0051]-[0057] that the heating device is in communication with a variety of bio-analysis devices capable of detecting the PCR product.

Response to Arguments

Applicant's arguments filed 05 March 2007 with respect to the 35 U.S.C. 103 rejections involving the combination of Wilding with Mowry and/or Doung have been fully considered but they are not persuasive.

Applicant's principle arguments are

(a) One of ordinary skill in the art would not be led to use the micropyrolyzer device of Mowry in the disposable biochip of Wilding. Additionally, the thermal controller of Doung is

Art Unit: 1797

not integrated into the individual biochip, and therefore does not suggest the presently claimed invention.

In response to Applicant's arguments, please consider the following comments.

Wilding discloses every structural feature set forth in the independent claims. Wilding clearly teaches (1) a disposable substrate, (2) a region of the substrate having components configured to interact with a biological substance, (3) a heating device, and (4) a bio-analysis device. Wilding teaches that the purpose of the heating device is to conduct PCR, and Wilding is silent as to whether or not the heating device is used to decontaminate the biochip. It is not suggested that one of ordinary skill in the art, after reviewing the teachings of Mowry and Doung, would add extra features to the apparatus of Wilding. Instead, one of ordinary skill in the art would be motivated to use the existing features disclosed by Wilding in new ways to achieve additional benefits. More specifically, a skilled practitioner would find it obvious to use the heater disclosed by Wilding to pyrolyze biological substances within the chip once the PCR assay is completed.

Conclusion

This is a non-final rejection.


No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nathan A. Bowers whose telephone number is (571) 272-8613. The examiner can normally be reached on Monday-Friday 8 AM to 5 PM.

Art Unit: 1797

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gladys Corcoran can be reached on (571) 272-1214. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



NAB



GLADYS JP CORCORAN
SUPERVISORY PATENT EXAMINER